News

Socioeconomic factors are a key risk factor for Type 2 diabetes, but a new analysis says the same is not true when it comes to Type 1 diabetes.

New research reveals AREDS vitamins do not slow geographic atrophy progression in AMD, urging patients to explore FDA-approved treatments instead.

Gazyva is the first and only anti-CD20 monoclonal antibody approved to treat kidney inflammation associated with lupus.

Here’s what you missed this week on Managed Healthcare Executive.

At the American Academy of Ophthalmology meeting, Andrew G. Lee, M.D., explained that El Niño and La Niña weather patterns—worsened by climate change—can worsen eye conditions such as dry eye, cataracts, infections, and UV-related damage while also influencing disease outbreaks and access to care.

A study using AAO's IRIS Registry demonstrates Eylea HD 8 mg improves vision in treatment-naive patients with wet age-related macular degeneration or diabetic macular edema with previously treated patients extending dosing intervals two weeks.

A phase 3 trial of Hernexeos (zongertinib) as a first-line treatment for patients with lung cancer tumors with HER2 mutations is underway.

Biosimilars enhance arthritis treatment access, with rising adoption among women and long-term patients, revealing key prescribing patterns in Turkey.

Daniel Henick, M.D., an ophthalmology resident at Yale-New Haven Medical Center, is raising awareness for pickleball injuries by encouraging players to wear protective eye gear during games.

New findings reveal significant geographic disparities in Medicare access, costs and quality, impacting millions of beneficiaries across the U.S.

The world’s first fixed triple therapy formula is already approved in more than 50 countries outside the United States.

Research reveals that even with over 25 million losing Medicaid during unwinding in 2023, the uninsured rate remains stable as many quickly re-enroll or switch coverage.

In this interview, Steven Buslovich, M.D., CMD, MS, chief medical officer of senior care at PointClickCare, explains the growing role of AI in healthcare, particularly in managing patient transitions between care settings.

In this video interview, Francesca Bridge, MBBS, neurologist at Alfred Health in Melbourne, Australia, and Ph.D. candidate at Monash University, shares why the results of her latest research were reassuring, but surprising.

Some menopause symptoms may be mistaken for multiple sclerosis symptoms in older women, new research finds.

In a historical public health move, the Maldives has eliminated mother-to-child HIV, syphilis and hepatitis B, which are collectively responsible for millions of deaths annually across the globe.

Here’s what you missed this week on Managed Healthcare Executive.

More than 60 abstracts will be presented from the ViiV portfolio, including updates from the phase 1 crossover study, the first comparing the acceptability and tolerability of long acting cabotegravir and lenacapavir injections after a single dose.

Experts discuss the implications of Most Favored Nation pricing on U.S. drug costs, innovation and patient access in the latest MJH Life Sciences webinar.

Vascular endothelial growth factor (VEGF) inhibitor, Eydenzelt (aflibercept-boav), is now approved to treat retinal disease marked by excessive blood vessel growth in adults.

Emergency Medicaid spending represented only 0.4% of total Medicaid expenditures in 2022, rising to 0.9% in states with higher populations of undocumented immigrants.

Back surgeries to address age-related pain in older adults aren’t just risky, they're expensive too, according to a recent study from the Lown Institute.

In this interview, Steven Buslovich, M.D., CMD, MS, CMO of Senior Care at PointClickCare describes AI’s role in care transitions within healthcare systems and how AI can reduce readmission rates.

Medicare beneficiaries face confusion during the Annual Enrollment Period, with significant plan changes ahead for 2026. Understanding options is crucial.

Older adults living with HIV face higher rates of opioid prescribing and opioid use disorder than their HIV-negative peers, according to new research from Rutgers University.

Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx.